

Ipsen overview

London Healthcare Conference – Bear Stearns
Mr Jacques-Pierre Moreau – Chief Scientific Officer
Mr David Schilansky – Investor Relations Officer
London, 27th February 2007



Disclaimer

This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management's current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated in the summary information. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this presentation to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based unless so required by applicable law.

All product names listed in this document are either licensed to the Ipsen Group or are registered trademarks of the Ipsen Group or its partners

Profile and strategy



An innovation driven International Specialty Pharma Group

A world-class Group

- > 100 countries. c.4,000 employees, founded in 1929.
- 2005 Sales: €807 m. 2005 EBIT: €185 m (23.0% margin).
- Market capitalisation (as of February 1, 2007): ~€3.0 bn

A diversified and balanced portfolio of products with more than 20 field proven products

A longstanding presence in primary care in France

A clear strategic focus on fast-growing specialist care worldwide

- 47% of 2005 Group sales, 45% in 2006
- Gastroenterology, cognitive disorders and cardiovascular.


A differentiating R&D capability

- 49% of 2005 Group sales, 52% in 2006
- Targeted Therapeutic areas:
Oncology, neuromuscular disorders and endocrinology
- Focused on (i) hormone-dependent diseases, (ii) peptide and protein engineering and (iii) innovative delivery systems.
- 700 staff, 2005 R&D expense: 20.9% of sales.


A recognised strategic partner

- Alliances with international industry leaders in US, Europe and Japan and best-in-class universities around the world.

A diversified and balanced portfolio of products




A market leader in our Targeted Therapeutic Areas




Targeted Therapeutic Areas and International markets drive our expansion

2005 and 2006 sales by therapeutic area



2005 and 2006 sales by geographical area



6

Strategy: Grow, Optimise, Globalise

Mission Statement

To be a worldwide best-in-class provider of innovative drugs, addressing unmet medical needs in its targeted therapeutic areas

Strategic Priorities

- 1 **GROW** top-line and profits in the Targeted Therapeutic Areas by providing innovative drug therapy
- 2 **OPTIMISE** returns of primary care through selected product life cycle management, partnerships and focused investments
- 3 **GLOBALISE** through active geographical expansion policy

Key Company Levers


- 1 **Strong R&D Capabilities**
- 2 **Extended International Network**
- 3 **Experienced and Proactive Teams**
- 4 **Financial Flexibility**

Key Growth Boosters

- 1 **US expansion** (4 NDAs)
- 2 **Strong R&D pipeline** (9 NCEs)
- 3 **Partnerships** (Medicis, Roche...)

7

Newsflow in 2006: Reshaping Ipsen's profile



A differentiating R&D



A unique convergence of capabilities

A differentiating R&D focused on...

- ① **Hormone dependent diseases**
- ② **Peptide and protein engineering**
- ③ **Innovative delivery systems**

A competitive R&D capability with...

- ④ **4 R&D specialized centres (Boston, Paris, Barcelona, London)**
- ⑤ **A staff of 700**
- ⑥ **20.9% of sales spent on R&D in 2005**
- ⑦ **A unique convergence of technological platforms**

A recognised strategic partner

Ipsen has built a strong network of centres of research excellence and industry leaders

10

A strong R&D pipeline to fuel future growth: 9 NCEs

NEW CHEMICAL ENTITIES

BN 83495 (STX 64)	Post-menopausal breast cancer	Phase I
BN 2629 (SJG-136)	Advanced metastatic cancers	Phase I
Diflomotecan (BN 80915)	Advanced metastatic cancers	Phase II
Elomotecan (BN 80927)	Advanced metastatic cancers	Phase I
Acapodene®	Treatment of Androgen Deprivation Therapy induced iatrogenic effects	Phase III
Increlex®	Severe primary IGF-1 deficiency	<u>Under regulatory review in the EU</u>
BIM 51077	Type 2 diabetes	Partnered with Roche
OBI-1®	Haemostasis	Phase II
Febuxostat®	Symptomatic hyperuricaemia	<u>Under regulatory review in the EU</u>

LIFE CYCLE MANAGEMENT PROGRAMMES

Decapeptyl®	Pre-menopausal breast cancer 4 -6months SRF (prostate)	Phase III Phase III
Somatuline Autogel®	Non functioning neuro endocrine tumors	Phase III
Somatuline Autogel®	Acromegaly	<u>Under regulatory review in the US</u>
Somatuline Autogel®	Co-administration with Pegvisomant	Phase III
NutropinAq®	Non-GH deficient short stature	<u>Under regulatory review in the EU</u>
Dysport®	Cervical Dystonia	Phase III US filing expected in 2007
Dysport®	Myofascial pain	Phase II
Reloxin®	Aesthetic medicine	<u>Under regulatory review in the EU</u> US: Partnered with Medicis - filing expected in 2007
Tanakan®	Mild cognitive impairment related to age	Phase III

11


Purple: Oncology / Green: Endocrinology / Blue: Neuromuscular disorders
In Bold: US projects - NDAs
This table excludes pre-clinical projects

BIM-51077: illustrating Ipsen's R&D capabilities

- ✓ Equal / greater potency compared to native compound
- ✓ Extended metabolic half-life: 22x more stable in plasma
- ✓ Complete retention of incretin properties
- ✓ Strong patent positions


- Roche opt-in in July 2006**
- ✓ €56 m paid upfront + €3 m in 2007
 - ✓ €170 m potential additional milestones
 - ✓ Mid-teens royalties on WW net sales

Designing the peptide itself...



Human GLP-1(7-36)NH₂ is cleaved in plasma at both N- & C termini: modification of positions 8 & 35

...so that it fits Ipsen's innovative delivery systems technologies



Syringe used for BIM51077 SRF: - 0.3mL TERUMO Myjector U-100 with 29G1/2 (0.33 X 12 mm)

12

Somatuline® Autogel® : convenient administration

	Somatuline® Autogel®	Sandostatin LAR®
Indications	Acromegaly, NET (EU only)	Acromegaly, NET
Administration route	Subcutaneous (s.c.)	Intramuscular (i.m.)
Volume injected	0.4 ml	2.0 ml
Needle length	20mm	40mm
Formulation	Ready to use	Powder for reconstitution



Comparison Of pre-filled (RHS) Versus competitor intramuscular injection device (LHS)



Somatuline® autogel®

lanreotide

13

Entering the North American market



US strategy: Creating a global endocrinology franchise with Tercica

- **Cross-Licensing agreement for Somatuline® Autogel® in North America and Increlex™ in Europe & other territories**
- **Ipsen becomes Tercica's largest shareholder, with a 25% stake and with the ability to increase its stake to 40%**

- ✓ **Implementation of Somatuline® US strategy**
- ✓ **Enhanced Endocrinology portfolio with the combination of Somatuline®, NutropinAq® and Increlex, creating a “global care solution” for patients suffering from growth disorders**
- ✓ **Building a platform in endocrinology in the US through a staged and flexible equity investment in Tercica**

US strategy: gaining exposure to the North American aesthetic market with Medicis

- Licensing agreement for Reloxin® in North America
- Restylane® & Reloxin® synergistic concept
- Fast growing US aesthetic market


- ✓ Implementation of Reloxin® US strategy with Medicis, a leading dermatology company in the US (#1 dermal filler, #1 sales force)
- ✓ Up to c. \$230 million in total upfront and milestones payments, including c. \$125 million already paid to Ipsen in 2006
- ✓ 30% royalty payment on Medicis' net sales (including supply price)

16

Outlook



Profitable growth



18


Full year 2006 objectives

	Objectives FY06	Actuals FY06	Actuals FY05
Sales	6.5 to 7.5% growth	+6.8%	+7.4%
Reported EBIT	21.5 to 22.0% ⁽¹⁾ (of sales)	March 19, 2007	23.0% (of sales)

NOTE 1: Including the negative impact of a non-recurring expense of €8.4 million paid in the first half of 2006 to Inamed and excluding any loss from associates from Tercia

19

Most of the building blocks are in place to further accelerate Ipsen's growth beyond 2006



Back-up #1

Financials



2005 financials at a glance

In € millions	2005	2004	05/04 growth
Sales	807.1	751.5	+7.4%
EBIT	185.3	156.5	+18.4%
EBIT margin	23.0%	20.8%	
Net profit	148.6	117.6	+26.4%
Net margin	18.4%	15.7%	
EPS ⁽¹⁾ (diluted - in € per share)	2.20	2.01	+9.5%
Cash flow from operations	176.9	124.7	+41.8%

Sales at constant perimeter


IFRS, pro forma, 2004 adjusted to exclude disposed GP business in Spain from continuing operations

Note (1): based on average number of shares during the period

22

IPSEN
Innovation for patient care

First half 2006 results highlights



23

NOTE: margins are calculated as % of sales
IFRS, H1-2005 pro forma

IPSEN
Innovation for patient care

First half 2006 P&L highlights

In €m	H1 06	H1 05	% chge	
Sales	430.6	404.1	+6.6%	
Other revenues	46.6	45.7	+1.9%	<ul style="list-style-type: none"> Other revenues: <ul style="list-style-type: none"> - Lower Kogenate royalties (€20.2m vs. €21.1 m LY) - Milestones from Medicis for Reloxin - Includes €10 million revenue from a research contract termination
Total revenues	477.2	449.8	+6.1%	
COGS	(88.9)	(84.4)	+5.3%	Improved COGS ratio
R&D	(83.8)	(75.6)	+10.9%	Significant increase in R&D costs <ul style="list-style-type: none"> - acceleration of BIM51077 program - FDA inspection preparation
SG&A	(188.0)	(174.2)	+7.9%	Increase in SG&A <ul style="list-style-type: none"> - payment of royalties to third parties - sales taxes in France - Listing requirements
Other income and expenses & restructuring costs	(8.1)	0.2	n.m.	Other income includes one-off payment of €8.4 m to Inamed: ca. 2 points impact on EBIT margin
Operating profit	108.4	115.8	(6.4)%	Improvement in financial result due to improved cash situation
<i>EBIT margin (as a % of total sales)</i>	<i>25.2%</i>	<i>28.7%</i>		Effective tax rate at 18.7% mainly due to tax loss carry forwards (recurring tax rate: 25%)
Adjusted operating profit	116.8	115.8	+0.8%	
Adjusted EBIT Margin (as a % of total sales)	27.1%	28.7%		
Financial result	0.4	(4.6)	n.m.	
Income tax	(20.3)	(22.3)	(8.9)%	
Net profit from continuing operations	88.4	88.9	n.m.	
Consolidated profit	88.5	89.6	(1.2%)	
Attributable to Ipsen shareholders	88.1	89.4		


24

IFRS, H1-2005 pro forma



Focus on other revenues evolution

- Royalties received**
 - mainly Kogenate® license (€20.2 million for 1H06 vs €21.1 million for 1H05)
 - 1H05 had been particularly high due to the carry over of some 2004 royalties into 2005
- Milestone payments**
 - mainly Reloxin® and Tenstaten® agreements
- Licensing agreements**
 - mainly recognition of advance payments made by Roche within the BIM51077 partnership
 - 1H05 includes an income of €10.0 million resulting from the termination of a research contract
- Other revenues**
 - higher billings for R&D services in the framework of existing partnerships
 - increase in co-promotion revenues: early termination of the co-promotion contract of Zoxan with Pfizer



25

IFRS, H1-2005 pro forma



Focus on “other revenues”: backlog of revenues

Milestones cashed-in before June 30, 2006 not yet recognized as revenues

(in € million)	30 June 06	30 June 05
Total milestones cashed-in:	94.3	5.0
<i>Recognized in time as revenues as follows:</i>		
H2 of year N	4.0	2.4
FY of year N+1	8.0	1.1
FY N+2 and beyond	82.3	1.5

Milestones cashed-in after June 30, 2006

(in € million)	
Total milestones cashed-in:	73.6
<i>Recognized in time as revenues as follows:</i>	
H2 2006	2.6
FY 2007	5.5
FY 2008 and beyond	65.5


Focus on SG&A evolution

Sales & Marketing

- Increase in royalties paid to third-parties
- Increase of the sales tax in France to 1.76% on January 1st, 2006 from 0.6% a year ago
- Increase of other expenses significantly below the sales growth level reflects the Group's productivity improvements

G&A

- Increase in costs at certain Corporate functions, notably:
 - stock exchange listing of the Group,
 - reinforcement of certain administrative functions related to the expansion in international markets



First half 2006 balance sheet highlights

	Assets (€m)		Liabilities and Shareholders' Equity (€m)	
	30-Jun-06	31-Dec-05	30-jun-06	31-Dec-05
Goodwill	188.8	188.8	Shareholders' Equity	672.7
Tangible Assets	186.1	187.8	Minority Interests	1.5
Intangible Assets	38.9	39.8	Long-Term Financial Debt	22.9
Other fixed Assets	55.4	18.4	Other non current liabilities	106.6
Total non-current Assets	469.2	434.8	Short-Term Financial Debt	8.6
Total Current Assets	556.0	495.0	Other current Liabilities	209.6
Incl. Cash and Equivalents	226.2	202.0	Liabilities associated with current asset held for sale	9.4
Non-current assets held for sale	6.1	12.7	Total Liabilities	1,031.3
Total Assets	1,031.3	942.5	Net (debt) / cash	193.3

IFRS, pro forma

28

First half 2006 cash-flow highlights

In €m	H1 06	H1 05
- Cash flow before variation in WCR	89.6	98.3
- (Increase) decrease in WCR	40.6	(35.8)
Net cash flow generated by operating activities	130.2	62.5
Net cash flow used in investment activities	(25.2)	(29.7)
Net cash flow used in financing activities	(82.4)	(88.4)
Net cash flow provided by discontinued activities	1.6	-
Increase (decrease) in cash flow	24.2	(55.6)
Cash and cash equivalent, beginning of year	200.6	92.8
Impact of <i>pro forma</i> treatment	-	(5.6)
Impact of foreign exchange variations	-	0.1
Cash and cash equivalent, end of period	224.8	31.7

- Notably the collection of payments received from Medicis not yet recognised as revenues
- Decrease of OAL
- Increase in inventories and trade receivables
- Tax payable increased resulting from the Medicis payment and by the balance of tax payable related to Group affiliates in France
- Capital expenditures required to maintain the Group's industrial facilities
- Following payments by Medicis, €31.1 million have been reimbursed on Group's credit facilities, therefore reducing utilization to €6.6 million.
- Dividend payment for €50.4 million (vs. €29.3 million in 2005)

29

IFRS, H1-2005 pro forma

Back-up #2

Tercica transaction details



Key terms of the cross licensing agreements

	Ipsen Commercialisation of Increlex	Tercica Commercialisation of Somatuline
Territory	Worldwide ex USA, Canada and Japan	USA and Canada
Duration	15 Years ¹	15 Years ¹
Upfront Payment	€10m (paid upon closing)	\$25m (paid with a convertible upon closing)
Milestone on MA grant	€15m (paid upon MA in EU)	€30m (paid with a convertible upon MA in U.S.)
Royalty on Net Sales	sliding scale (from 15 to 25%) based upon net sales of the product, in addition to supply price of 20% of net sales	sliding scale (from 15 to 25%) based upon net sales of the product, in addition to supply price of 20% of net sales

NOTE1: The longer of the patent protection or 15 years. Period after which licence is fully paid and irrevocable

A staged investment in Tercica


	Cumulative Stake	Consideration	Price per Share (\$)	Total Amount (€m)	Comments
1 Equity Investment	25.0%	Cash	\$6.17	€1.8m	• 30% premium over the 15-days weighted average share price
2 Convertible Notes 1&2	27.5% ¹	Somatuline Rights	\$7.41	€20.0m	• Convert 1 issued at closing and Convert2 at FDA approval for Somatuline US • Issued against Somatuline Rights (no cash considerations) • 2.5% PIK coupon not taken into account
	33.3% ¹		\$7.41	€30.0m	
3 Convertible Note 3	35.4% ¹	Cash	\$7.41	€12.0m	• Issued for cash at FDA approval • 2.5% PIK coupon not taken into account
4 Warrants (Illustrative figures)	40.0% ¹	Cash	\$7.41	€9.3m	• Issued for free in order to reach 40% if necessary • The number of warrants will be adjusted for Tercica share issuance

Total equity stake: 40.0% **Total cash out excluding warrants: €73.7 million**

Note 1: Fully diluted stake. The fully diluted number of shares includes the dilution of the investment and of all outstanding options / warrants

32

A rich Endocrinology pipeline



33

Back-up #3

Product information



Decapeptyl® at a Glance



Classification

- Ephmra class: H1C et L2A
- ATC code: L2A
- Active substance: triptorelin

Mechanism of Actions

- Analogue of GnRH

Territories

- Approved in more than 60 countries, including 25 in Europe
- Exclusive rights held by Ipsen for the marketing of Decapeptyl in EU (except Sweden) and in several other countries

Approved Indications / Prevalence

- Prostate cancer
 - 1.2% of men over 50 years old in Europe ⁽¹⁾
- Endometriosis
 - 10% of reproductive-aged women ⁽²⁾
- Fibroid tumors (uterine leiomyomas)
 - 20% to 25% of reproductive age women ⁽³⁾
- Precocious puberty
 - 0.05% of children aged 6 to 8 years old ⁽⁴⁾
- Female infertility (in vitro fertilisation)
 - 14% of reproductive-aged women ⁽²⁾

Target Audience

- Urologists
- Oncologists
- Andrologists, Radiotherapy specialists, Paediatricians-endocrinologists, Gynaecologists, Obstetricians and IVF specialists

Patent Position

- US and Europe patent expiring in 2010

Source: (1) DaVinci Cancer Perspectives 2005; (2) Datamonitor, Endometriosis; (3) Cancer Weekly; (4) Diagnostics Business Matters

Somatuline® at a Glance



Classification

- Ephra class: H4V
- ATC code: H1C
- Active substance: lanreotide

Mechanism of action

- Analogue of somatostatin

Territories

- Approved in more than 50 countries (including more than 25 in Europe)
- Indicated for acromegaly and symptoms associated with neuroendocrine tumors (NET) in most countries
- Worldwide exclusive production and marketing rights owned by Ipsen (for both Somatuline® and Somatuline® Autogel®)

Approved Indications / Prevalence

- Symptomatic treatment of acromegaly
 - 60 per million inhabitants ⁽¹⁾
- Relief of symptoms associated with neuroendocrine tumors (carcinoids)
 - 15 per million inhabitants ⁽²⁾

Target Audience

- Endocrinologists
- Gastroenterologists
- Oncologists

Patent Position

- Somatuline® Autogel® : US and Europe patent expiring in 2015
- Somatuline® : Europe patent expiring in 2009 for most countries

Source: (1) *Clinical Endocrinology*; (2) C. Tebbi, MD; eMedicine

36



Dysport® at a Glance



Classification

- ATC code: M3A, S1X

Mechanism of action

- Active substance: Botulinum toxin of Type A

Target Audience

- Neurologists
- Physical medicine and rehabilitation
- Neuro-paediatricians, Ear-nose and throat specialists, Ophthalmologists
- Dermatologists, Plastic surgeons

Approved Indications / Prevalence

- Hemifacial spasm
 - 11 per 100,000 inhabitants ⁽¹⁾
- Blepharospasm
 - 5 per 100,000 inhabitants ⁽²⁾
- Spasmodic torticollis
 - 9 per 100,000 inhabitants ⁽³⁾
- Adult arm spasticity and Adult leg spasticity
 - 322 per 100,000 inhabitants ⁽⁴⁾
- Paediatric cerebral palsy spasticity
 - 19 per 100,000 persons aged 17 and less ⁽⁴⁾
- Glabellar Lines (Brazil, Mexico, Russia)

Territories

- First launch in the UK in 1991
- Approved in more than 70 countries

Patent Position

- No patent

Source: (1) *Q J Med* V95; (2) www.blepharospasm.org; (3) *Movement disorders* V10; (4) www.cdc.gov.

37



Primary Care: a strong historic presence in France

Tanakan®

- Field-proven over 30 years, very strong brand name in France
- On-going large scale clinical trials in Europe and US (NIH) in Alzheimer prevention. First EU Alzheimer indication approval granted in Belgium in 2004
- Competitors: Trivastal (Servier), Praxilene (Lipha Santé), Sermion (Sanofi-Aventis)

Smecta®

- Strong brand recognition in all its markets by patients and doctors
- Cost-effective and field proven product for more than 25 years with very favourable safety profile
- Long-standing know-how in clay sourcing
- Competitors: Imodium and Arestal (Janssen Cilag), Ercefuryl (Sanofi-Aventis)

Forlax®

- 1st clinical development in paediatric field for a constipation drug
- Cost-effective and field proven product (launched in 1996) with very favourable safety profile
- Competitors: Duphalac (Solvay Pharma), Movicol (Norgine Pharma)

38

Contacts & useful information

Investor Relations contact:

David Schilansky

+33 (0) 1 4430 4388
david.schilansky@ipsen.com

Stock info:

Outstanding number of shares (February 2007): 84,024,683
Approx. market capitalisation (February 2007): ~€3.0 bn

Tickers

BBG: IPN FP
RTRS: IPN.PA

Listing

Euronext Paris

39